Country: Canada
Language: English
Source: Health Canada
CEFTRIAXONE (CEFTRIAXONE SODIUM)
SANDOZ CANADA INCORPORATED
J01DD04
CEFTRIAXONE
1G
POWDER FOR SOLUTION
CEFTRIAXONE (CEFTRIAXONE SODIUM) 1G
INTRAMUSCULAR
100
Prescription
THIRD GENERATION CEPHALOSPORINS
Active ingredient group (AIG) number: 0117292003; AHFS:
CANCELLED PRE MARKET
2018-08-01
_ _ PRODUCT MONOGRAPH SANDOZ CEFTRIAXONE Sterile Ceftriaxone for Injection BP 1 G AND 2 G CEFTRIAXONE PER VIAL (INCORPORATED AS CEFTRIAXONE SODIUM) ANTIBIOTIC Sandoz Canada Inc. Date of Revision: January 15, 2010 145 Jules-Léger Boucherville, QC, Canada J4B 7K8 CONTROL # : 133307 _Sandoz Ceftriaxone _ _ Page 2 of 51_ _ _ TABLE OF CONTENTS HEALTH PROFESSIONAL INFORMATION......................................................................... 3 ACTION ..................................................................................................................................... 3 INDICATIONS AND CLINICAL USES................................................................................... 3 CONTRAINDICATIONS .......................................................................................................... 4 WARNINGS............................................................................................................................... 4 PRECAUTIONS......................................................................................................................... 6 ADVERSE REACTIONS........................................................................................................... 8 SYMPTOMS AND TREATMENT OF OVERDOSAGE ....................................................... 10 DOSAGE AND ADMINISTRATION..................................................................................... 10 ADMINISTRATION................................................................................................................ 11 PHARMACEUTICAL INFORMATION................................................................................. 13 DRUG SUBSTANCE............................................................................................................... 13 DRUG PRODUCT.................................................................................................................... 13 RECONSTITUTION ....................................................................................... Read the complete document